109 related articles for article (PubMed ID: 6784699)
1. Polymerised autologous tumor tissue particles in experimental cancer immunotherapy with special reference to the effects on the immune system of the host.
Syrjänen KJ; Soimakallio S
Arch Geschwulstforsch; 1980; 50(8):724-34. PubMed ID: 6784699
[TBL] [Abstract][Full Text] [Related]
2. Immunological reactivity in the lymph nodes of the host following experimental cancer immunotherapy utilizing polymerized autologous tumor tissue particles.
Syrjänen KJ; Soimakallio S
Neoplasma; 1980; 27(4):387-98. PubMed ID: 6779210
[TBL] [Abstract][Full Text] [Related]
3. Experimental cancer immunotherapy in DBA/2 mouse-mastocytoma model utilizing autologous tumor tissue polymerised with ethylchlorformiate.
Soimakallio S; Syrjänen KJ
Exp Pathol (Jena); 1980; 18(6):346-52. PubMed ID: 6774879
[TBL] [Abstract][Full Text] [Related]
4. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
5. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
6. Combined cytolytic effect of x irradiation and cell-mediated immune reactions on tumor cells in vitro.
Song CW; Levitt SH
Radiology; 1974 Apr; 111(1):211-2. PubMed ID: 4205812
[No Abstract] [Full Text] [Related]
7. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
8. [The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815].
Rakhmilevich AL; Rakhimova MS
Biull Eksp Biol Med; 1989 Dec; 108(12):721-4. PubMed ID: 2517487
[TBL] [Abstract][Full Text] [Related]
9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
11. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
12. [Immunological analysis of chemotherapeutic effects for the effective immunochemotherapy against cancer].
Yamada Y
Hokkaido Igaku Zasshi; 1984 Nov; 59(6):721-7. PubMed ID: 6397415
[TBL] [Abstract][Full Text] [Related]
13. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide derivative-coupled tumor cells.
Fujiwara H; Shima J; Sano H; Kosugi A; Nakajima H; Hamaoka T
Prog Clin Biol Res; 1987; 244():335-44. PubMed ID: 2958872
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
16. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
17. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
19. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
20. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
